Background: The 503A Compounding Framework
The FDA's 503A compounding framework governs which bulk drug substances can be legally prepared by licensed compounding pharmacies for individual patients with valid prescriptions.
Under this framework, substances are categorized as follows:
For the peptide research community, this categorization directly determines whether a compound can be accessed through a legitimate, regulated medical pathway — or only through grey-market research-use-only channels.
The February 2026 Announcement
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides currently on the Category 2 interim list would be moved to Category 1.
Peptides confirmed or reported to be included in the reclassification include:
The formal rulemaking process to implement these changes was initiated following the announcement. Until finalized, the compounds remain in legal limbo — the announcement signals intent, not yet enforcement policy change.
BPC-157: A Separate Track
BPC-157 was placed on the FDA Category 2 list in 2023 — effectively prohibiting its compounding under 503A. The February 2026 announcement did not explicitly confirm BPC-157's inclusion in the reclassification.
However, a 2026 update from HHS noted a pending reclassification back to Category 1 for BPC-157, which would restore the compounding pathway. As of mid-2026, BPC-157 remains in regulatory flux.
This is relevant context: the existing evidence base (a 2025 systematic review in HSS Journal covering 544 studies, a 2025 IV safety pilot, and an emerging 2026 narrative review) represents a meaningful strengthening of the scientific foundation that may support a Category 1 placement.
TB-500: Confirmed Category 2
TB-500 (thymosin beta-4 fragment 17-23) was reclassified as a 503A Category 2 bulk drug substance in February 2026. This means it is prohibited from use in compounded medications under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act as of that date.
This is a distinct regulatory track from full-length thymosin beta-4 (Tβ4), which has an active IND for clinical investigation (the RGN-259 ophthalmic program).
What Category 1 Means in Practice
When a peptide achieves Category 1 status:
This represents a fundamentally different — and safer — access pathway than grey-market research-use-only vendors, where independent testing has found purity discrepancies in roughly 15–20% of certificates of analysis.
Enforcement Actions Escalated in 2025
The regulatory landscape tightened significantly in 2025:
This enforcement escalation makes the Category 1 reclassification pathway increasingly consequential — it is now the primary route toward legitimate, supervised access for peptides with a legitimate medical rationale.
Implications for Research
For researchers and protocols covered on this site:
| Peptide | Current Status (mid-2026) |
|---|---|
| Semaglutide (GLP-1) | FDA-approved (Wegovy®, Ozempic®) |
| Tirzepatide (GLP-2) | FDA-approved (Zepbound®, Mounjaro®) |
| Tesamorelin | FDA-approved (Egrifta®) |
| PT-141 | FDA-approved (Vyleesi®) |
| Semax | Moving to Category 1 |
| Selank | Moving to Category 1 |
| Epithalon | Moving to Category 1 |
| BPC-157 | Category 2 (pending review) |
| TB-500 | Category 2 |
| IGF-1 LR3 | Category 2 |
| Ipamorelin | Category 1 |
| CJC-1295 no DAC | Category 1 |
| Sermorelin | Category 1 |
| NAD+ | Category 1 (injectable) |
| GHK-Cu | Category 1 |
Regulatory status can change. This table reflects the best available information as of mid-2026 and should not be relied upon as legal advice.
Important Note
This article is for educational and research reference purposes only. Regulatory status affects legal access pathways but does not constitute a medical recommendation. Consult a licensed healthcare provider before pursuing any peptide protocol.